Predicting individual responses to lithium with oxidative stress markers in drug-free bipolar disorder

Reference

• Andreazza AC, Kapczinski F, Kauer-Sant'Anna M, Walz JC, Bond DJ, Goncalves CA, Young LT, Yatham LN. 2009. 3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder. J Psychiatry Neurosci. 34(4):263–271.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN. 2008a. Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord. 111(2–3):135–144.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Kauer-Sant'Anna M, Frey BN, Stertz L, Zanotto C, Ribeiro L, Giasson K, Valvassori SS, Reus GZ, Salvador M, et al. 2008b. Effects of mood stabilizers on DNA damage in an animal model of mania. J Psychiatry Neurosci. 33(6):516–524.
   PubMed Web of Science ®Google Scholar
• Andreazza AC, Shao L, Wang JF, Young LT. 2010. Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder. Arch Gen Psychiatry. 67(4):360–368.
   PubMed Web of Science ®Google Scholar
• Angelova PR, Abramov AY. 2018. Role of mitochondrial ROS in the brain: from physiology to neurodegeneration. FEBS Lett. 592(5):692–702.
   PubMed Web of Science ®Google Scholar
• Bengesser SA, Lackner N, Birner A, Platzer M, Fellendorf FT, Queissner R, Filic K, Reininghaus B, Wallner-Liebmann SJ, Mangge H, et al. 2016. Mood stabilizers, oxidative stress and antioxidative defense in euthymia of bipolar disorder. CNS Neurol Disord Drug Targets. 15(4):381–389.
   PubMed Web of Science ®Google Scholar
• Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI. 2008. N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry. 64(6):468–475.
   PubMed Web of Science ®Google Scholar
• Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, et al. 2011a. The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord. 135(1–3):389–394.
   PubMed Web of Science ®Google Scholar
• Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yucel M, Gama CS, Dodd S, Dean B, et al. 2011b. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 35(3):804–817.
   PubMed Web of Science ®Google Scholar
• Brown NC, Andreazza AC, Young LT. 2014. An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res. 218(1–2):61–68.
   PubMed Web of Science ®Google Scholar
• Che Y, Wang JF, Shao L, Young T. 2010. Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. J Psychiatry Neurosci. 35(5):296–302.
   PubMed Web of Science ®Google Scholar
• de Sousa RT, Zarate CA, Jr., Zanetti MV, Costa AC, Talib LL, Gattaz WF, Machado-Vieira R. 2014. Oxidative stress in early stage Bipolar Disorder and the association with response to lithium. J Psychiatr Res. 50:36–41.
   PubMed Web of Science ®Google Scholar
• Depp CA, Mausbach BT, Harvey PD, Bowie CR, Wolyniec PS, Thornquist MH, Luke JR, McGrath JA, Pulver AE, Patterson TL. 2010. Social competence and observer-rated social functioning in bipolar disorder. Bipolar Disord. 12(8):843–850.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Turkin S, Houck PR, Soreca I, Kupfer DJ. 2008. Metabolic syndrome in patients with bipolar disorder. J Clin Psychiatry. 69(4):678–679.
   PubMed Web of Science ®Google Scholar
• Floyd RA. 1999. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med. 222(3):236–245.
   PubMed Web of Science ®Google Scholar
• Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA, Leboyer M, Berk M, Malhi GS, Lopez-Jaramillo C, et al. 2013. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 47(4):321–332.
   PubMed Web of Science ®Google Scholar
• Frey BN, Martins MR, Petronilho FC, Dal-Pizzol F, Quevedo J, Kapczinski F. 2006a. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord. 8(3):275–280.
   PubMed Web of Science ®Google Scholar
• Frey BN, Valvassori SS, Gomes KM, Martins MR, Dal-Pizzol F, Kapczinski F, Quevedo J. 2006b. Increased oxidative stress in submitochondrial particles after chronic amphetamine exposure. Brain Res. 1097(1):224–229.
   PubMedGoogle Scholar
• Frey BN, Valvassori SS, Reus GZ, Martins MR, Petronilho FC, Bardini K, Dal-Pizzol F, Kapczinski F, Quevedo J. 2006c. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci. 31(5):326–332.
   PubMed Web of Science ®Google Scholar
• Frey BN, Valvassori SS, Reus GZ, Martins MR, Petronilho FC, Bardini K, Dal-Pizzol F, Kapczinski F, Quevedo J. 2006d. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res. 31(5):699–703.
   PubMed Web of Science ®Google Scholar
• Gold AK, Otto MW, Deckersbach T, Sylvia LG, Nierenberg AA, Kinrys G. 2018. Substance use comorbidity in bipolar disorder: a qualitative review of treatment strategies and outcomes. Am J Addict. 27(3):188–201.
   PubMed Web of Science ®Google Scholar
• Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, O'Donovan C, Alda M. 2002. Is response to prophylactic lithium a familial trait? J Clin Psychiatry. 63(10):942–947.
   PubMed Web of Science ®Google Scholar
• Hajek T, McIntyre R, Alda M. 2016. Bipolar disorders, type 2 diabetes mellitus, and the brain. Curr Opin Psychiatry. 29(1):1–6.
   PubMed Web of Science ®Google Scholar
• Hansson C, Joas E, Palsson E, Hawton K, Runeson B, Landen M. 2018. Risk factors for suicide in bipolar disorder: a cohort study of 12 850 patients. Acta Psychiatr Scand. 138(5):456–463.
   PubMed Web of Science ®Google Scholar
• Kapczinski F, Dal-Pizzol F, Teixeira AL, Magalhaes PV, Kauer-Sant'Anna M, Klamt F, Moreira JC, de Bittencourt Pasquali MA, Fries GR, Quevedo J, et al. 2011. Peripheral biomarkers and illness activity in bipolar disorder. J Psychiatr Res. 45(2):156–161.
   PubMed Web of Science ®Google Scholar
• Kartalci S, Karabulut AB, Ozcan AC, Porgali E, Unal S. 2011. Acute and chronic effects of electroconvulsive treatment on oxidative parameters in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry. 35(7):1689–1694.
   PubMed Web of Science ®Google Scholar
• Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ. 2012. Can bipolar disorder be viewed as a multi-system inflammatory disease? J Affect Disord. 141(1):1–10.
   PubMed Web of Science ®Google Scholar
• Lenaz G, D’Aurelio M, Merlo Pich M, Genova ML, Ventura B, Bovina C, Formiggini G, Parenti Castelli G. 2000. Mitochondrial bioenergetics in aging. Biochim Biophys Acta. 1459(2–3):397–404.
   PubMed Web of Science ®Google Scholar
• Li Z, Wang Z, Zhang C, Chen J, Su Y, Huang J, Yi Z, Yuan C, Hong W, Wang Y, et al. 2017. Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: result from a prospective longitudinal study. Psychoneuroendocrinology. 81:113–121.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang C, Fan J, Yuan C, Huang J, Chen J, Yi Z, Wang Z, Hong W, Wang Y, et al. 2014. Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. Br J Psychiatry. 205(1):29–35.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. 2017. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxid Med Cell Longev. 2017:2525967.
   PubMed Web of Science ®Google Scholar
• Macedo DS, de Lucena DF, Queiroz AI, Cordeiro RC, Araujo MM, Sousa FC, Vasconcelos SM, Hyphantis TN, Quevedo J, McIntyre RS, et al. 2013. Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry. 43:230–237.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V, Jr., da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, et al. 2007. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett. 421(1):33–36.
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Luckenbaugh DA, Soeiro-de-Souza MG, Marca G, Henter ID, Busnello JV, Gattaz WF, Zarate CA. Jr 2013. Early improvement with lithium in classic mania and its association with later response. J Affect Disord. 144(1–2):160–164.
   PubMed Web of Science ®Google Scholar
• Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D. 2010. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem. 17(36):4511–4520.
   PubMed Web of Science ®Google Scholar
• Mangge H, Hubmann H, Pilz S, Schauenstein K, Renner W, Marz W. 2004. Beyond cholesterol-inflammatory cytokines, the key mediators in atherosclerosis. Clin Chem Lab Med. 42(5):467–474.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Danilewitz M, Liauw SS, Kemp DE, Nguyen HT, Kahn LS, Kucyi A, Soczynska JK, Woldeyohannes HO, Lachowski A, et al. 2010. Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord. 126(3):366–387.
   PubMed Web of Science ®Google Scholar
• Morgan VA, Mitchell PB, Jablensky AV. 2005. The epidemiology of bipolar disorder: sociodemographic, disability and service utilization data from the Australian National Study of Low Prevalence (Psychotic) Disorders. Bipolar Disord. 7(4):326–337.
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 349(9064):1498–1504.
   PubMed Web of Science ®Google Scholar
• Nucifora LG, Tanaka T, Hayes LN, Kim M, Lee BJ, Matsuda T, Nucifora FC, Jr., Sedlak T, Mojtabai R, Eaton W, et al. 2017. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl Psychiatry. 7(8):e1215.
   PubMedGoogle Scholar
• Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. 2004. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol. 19:89–95.
   PubMed Web of Science ®Google Scholar
• Pfaffenseller B, Fries GR, Wollenhaupt-Aguiar B, Colpo GD, Stertz L, Panizzutti B, Magalhaes PV, Kapczinski F. 2013. Neurotrophins, inflammation and oxidative stress as illness activity biomarkers in bipolar disorder. Expert Rev Neurother. 13(7):827–842.
   PubMed Web of Science ®Google Scholar
• Raffa M, Barhoumi S, Atig F, Fendri C, Kerkeni A, Mechri A. 2012. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry. 39(2):371–375.
   PubMed Web of Science ®Google Scholar
• Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. 1991. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry. 30(4):409–412.
   PubMed Web of Science ®Google Scholar
• Rosa AR, Singh N, Whitaker E, de Brito M, Lewis AM, Vieta E, Churchill GC, Geddes JR, Goodwin GM. 2014. Altered plasma glutathione levels in bipolar disorder indicates higher oxidative stress; a possible risk factor for illness onset despite normal brain-derived neurotrophic factor (BDNF) levels. Psychol Med. 44(11):2409–2418.
   PubMed Web of Science ®Google Scholar
• Rowland T, Perry BI, Upthegrove R, Barnes N, Chatterjee J, Gallacher D, Marwaha S. 2018. Neurotrophins, cytokines, oxidative stress mediators and mood state in bipolar disorder: systematic review and meta-analyses. Br J Psychiatry. 213(3):514–525.
   PubMed Web of Science ®Google Scholar
• Schoepf D, Heun R. 2014. Bipolar disorder and comorbidity: increased prevalence and increased relevance of comorbidity for hospital-based mortality during a 12.5-year observation period in general hospital admissions. J Affect Disord. 169:170–178.
   PubMed Web of Science ®Google Scholar
• Selek S, Savas HA, Gergerlioglu HS, Bulbul F, Uz E, Yumru M. 2008. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. J Affect Disord. 107(1–3):89–94.
   PubMed Web of Science ®Google Scholar
• Sies H. 1991. Oxidative stress: from basic research to clinical application. Am J Med. 91(3C):31S–38S.
   PubMed Web of Science ®Google Scholar
• Steckert AV, Valvassori SS, Moretti M, Dal-Pizzol F, Quevedo J. 2010. Role of oxidative stress in the pathophysiology of bipolar disorder. Neurochem Res. 35(9):1295–1301.
   PubMed Web of Science ®Google Scholar
• Tsai MC, Huang TL. 2015. Thiobarbituric acid reactive substances (TBARS) is a state biomarker of oxidative stress in bipolar patients in a manic phase. J Affect Disord. 173:22–26.
   PubMed Web of Science ®Google Scholar
• Vieta E, Popovic D, Rosa AR, Solé B, Grande I, Frey BN, Martinez-Aran A, Sanchez-Moreno J, Balanzá-Martínez V, Tabarés-Seisdedos R, et al. 2013. The clinical implications of cognitive impairment and allostatic load in bipolar disorder. Eur Psychiatry. 28(1):21–29.
   PubMed Web of Science ®Google Scholar
• Wang JF, Shao L, Sun X, Young LT. 2009. Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord. 11(5):523–529.
   PubMed Web of Science ®Google Scholar
• Yang Y, Bazhin AV, Werner J, Karakhanova S. 2013. Reactive oxygen species in the immune system. Int Rev Immunol. 32(3):249–270.
   PubMed Web of Science ®Google Scholar
• Zorov DB, Juhaszova M, Sollott SJ. 2014. Mitochondrial reactive oxygen species (ROS) and ROS-induced ROS release. Physiol Rev. 94(3):909–950.
   PubMed Web of Science ®Google Scholar